The role of the microbiome in NAFLD and NASH
Open accessThe DOI matches its Crossref record; 124 of the 125 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of cardiometabolic syndrome, which often also includes obesity, diabetes, and dyslipidemia. It is rapidly becoming the most prevalent liver disease worldwide. A sizable minority of NAFLD patients develop nonalcoholic steatohepatitis (NASH), which is characterized by inflammatory changes that can lead to progressive liver damage, cirrhosis, and hepatocellular carcinoma. Recent studies have shown that in addition to genetic predisposition and diet, the gut microbiota affects hepatic carbohydrate and lipid metabolism as well as influences the balance between pro‐inflammatory and anti‐inflammatory effectors in the liver, thereby impacting NAFLD and its progression to NASH. In this review, we will explore the impact of gut microbiota and microbiota‐derived compounds on the development and progression of NAFLD and NASH, and the unexplored factors related to potential microbiome contributions to this common liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Activation of these TLRs can contribute to the development of NAFLD and nonalcoholic steatohepatitis (NASH), with the most extensively studied pathway being LPS-TLR4 signaling.180”
From Interaction between microbiota and immunity in health and disease (2020) · cites this paper as [180]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Changes of Intestinal Functions in Liver Cirrhosis
Fukui, H., & Wiest, R. (2016) · Inflammatory Intestinal Diseases · doi:10.1159/000444436 · Cited by 6,808
Metabolic Endotoxemia Initiates Obesity and Insulin Resistance
Cani, P. D., Amar, J., Iglesias, M. A., Poggi, M., Knauf, C., Bastelica, D., Neyrinck, A. M., Fava, F., Tuohy, K. M., Chabo, C., et al. (2007) · Diabetes · doi:10.2337/db06-1491 · Cited by 6,638
The gut microbiota as an environmental factor that regulates fat storage
Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F., & Gordon, J. I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407076101 · Cited by 6,245 · cited 2×
“However, conven-tionalization of germ-free mice with normal mouse microbiota induces de novo hepatic lipogenesis, in addition to increased body fat content and insulin resistance (Ba¨ckhed et al , 2004).”
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis
Koeth, R. A., Wang, Z., Levison, B. S., Buffa, J. A., Org, E., Sheehy, B. T., Britt, E. B., Fu, X., Wu, Y., Li, L., et al. (2013) · Nature Medicine · doi:10.1038/nm.3145 · Cited by 4,386
Intestinal mucosal barrier function in health and disease
Turner, J. R. (2009) · Nature reviews. Immunology · doi:10.1038/nri2653 · Cited by 3,952 · cited 1×
“Under physiological conditions, tight junction proteins, such as zonula occludens, seal adjacent epithelial cells at the apical sites and prevent bacteria from entering the intestinal mucosa and the bloodstream (Turner, 2009).”
Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice
Ridaura, V. K., Faith, J. J., Rey, F. E., Cheng, J., Duncan, A. E., Kau, A. L., Griffin, N. W., Lombard, V., Henrissat, B., Bain, J. R., et al. (2013) · Science · doi:10.1126/science.1241214 · Cited by 3,788 · cited 1×
“…in the digestion of food and facilitates the absorption of the dietary molecules into the portal and systemic circulation (Jumpertz et al , 2011; Ridaura et al , 2013), interacts with the mucosal immune system, to shape development of its antigen recognition, recruitment, proliferation, and…”
Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43
Maslowski, K. M., Vieira, A. T., Ng, A., Kranich, J., Sierro, F., Yu, D., Schilter, H. C., Rolph, M. S., Mackay, F., Artis, D., et al. (2009) · Nature · doi:10.1038/nature08530 · Cited by 3,241 · cited 3×
“In addition, SCFAs are also potent signaling molecules through binding to G-protein-coupled receptors GPR41, GPR43, and GPR109A (Samuel et al , 2008; Maslowski et al , 2009).”
Research works printed but not linked: 1
- Ackermann D, Schutze H (1910) The formation of trimethylamine by bacterium prodigiosum. Zentralb Physiol 24: 210–211
Cited by
Items 401–500 of 548
Associations of Ultrasound Findings with Serum Iron and Ferritin Levels in Children with Obesity
Stepan, M. D., Vintilescu, Ş. B., Ionele, C. M., Dumitra, G. G., Podeanu, M.-A., Bigea, C. C., Sacerdoțianu, V. M., Anastasescu, C. M., & Florescu, D. N. (2024) · Life · doi:10.3390/life14040484 · Cited by 6
Lee, H. Y., & Yoon, E. L. (2025) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2025.027 · Cited by 5
Liver gene regulatory networks: Contributing factors to nonalcoholic fatty liver disease
Cebola, I. (2020) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1480 · Cited by 5
Efficacy and Mechanism of Mallotus furetianus Müll. Arg. Extract on Nonalcoholic Fatty Liver Disease
Lin, D., Ding, Y., Cheng, Y.-B., Chen, Y., Tang, Y., Wu, X., & Cheng, Y. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/4897463 · Cited by 5
Liver Microbiome in Healthy Rats: The Hidden Inhabitants of Hepatocytes
Sun, X., Zhang, H., Zhang, X., Xin, P. F., Gao, X., Li, H. R., Zhou, C. Y., Gao, W. M., Kou, X. X., & Zhang, J. G. (2023) · Cellular Microbiology · doi:10.1155/2023/7369034 · Cited by 5
Dysfunctional T Follicular Helper Cells Cause Intestinal and Hepatic Inflammation in NASHPreprint
Wang, H., Barrow, F., Fredrickson, G., Florczak, K. L., Nguyen, H. T., Parthiban, P., Herman, A., Adeyi, O. A., Staley, C. M., Ikramuddin, S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.07.544061 · Cited by 5
Li, L., Ji, L., Chen, J., Hou, S., Yang, Y., Wang, W., Lei, B., Zhang, W., Zhao, K., Zhao, Z., et al. (2024) · Veterinary Microbiology · doi:10.1016/j.vetmic.2024.110332 · Cited by 4
Arshad, F., Chinnappan, R., Broering, D. C., Raptis, D. A., Mir, T. A., Khan, M. I., & Yaqinuddin, A. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1748835 · Cited by 4
The versatile interplay between steatotic liver disease and liver cancer
Rahbari, M., Gris‐Oliver, A., Ramadori, P., Aicher, D., Sia, D., MALEK, N. P., Loomba, R. S., Bataller, R. A., Llovet, J. M., & Heikenwälder, M. F. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00918-y · Cited by 4
Qiao, S., Fan, S. Y., Xu, J., Xu, Z., Peng, C., Qu, J., Bing, Z., Zhou, S., Shen, S., Xu, G., et al. (2026) · Advanced Science · doi:10.1002/advs.202514830 · Cited by 4
Liu, Q., Fan, G., Bi, J., Qin, X., Fang, Q., Wu, M., Mei, S., Wan, Z., Lv, Y., Wang, Y., et al. (2024) · Exposure and Health · doi:10.1007/s12403-024-00629-5 · Cited by 4
Wyss, J., Raselli, T., Wyss, A., Telzerow, A., Rogler, G., Krupka, N., Yılmaz, B., Schmidt, T., & Misselwitz, B. (2024) · BMC Microbiology · doi:10.1186/s12866-024-03195-7 · Cited by 4
Type III Secretion System in Intestinal Pathogens and Metabolic Diseases
Zhou, L., Zhang, Y., Wu, S., Kuang, Y., Jiang, P., Zhu, X., & Yin, K. (2024) · Journal of Diabetes Research · doi:10.1155/2024/4864639 · Cited by 4
HCC in MASLD and ALD: Biochemical Pathways, Epidemiology, Diagnosis, and Treatment
Patel, S. A., Kasem, F., Flaherty, D. T., & Barve, A. J. (2025) · BioChem · doi:10.3390/biochem5030019 · Cited by 6
Liu, Y., Lv, H., Zhang, H., Li, H., Wang, A., Yu, S., He, Q., Chen, S., Wang, J., Ran, X., et al. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.124113 · Cited by 4
Cong, S., Wang, S., Qiao, Y., Gu, S., Susu, L., Chai, X., & Yongsheng, Z. (2023) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.460 · Cited by 4
Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease
Hartl, L., Elias, J., Prager, G., Reiberger, T., & Unger, L. W. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i19.2281 · Cited by 4
Zhang, Y., Li, J., Zhang, Y., & Wang, Y. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i23.6654 · Cited by 4
Dionisi, T., Galasso, L., Antuofermo, L., Mancarella, F. A., Esposto, G., Mignini, I., Ainora, M. E., Gasbarrini, A., Addolorato, G., & Zocco, M. A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247799 · Cited by 3
Recent advances in the treatment of non-alcoholic fatty liver disease with astragaloside IV
Wang, H., Jiang, Y., Wang, S., Lu, C., Tang, L., Gu, T., & Shu, S. (2025) · Acta Pharmaceutica · doi:10.2478/acph-2025-0022 · Cited by 3
Clinical and molecular implications of antipsychotics in MASLD
Gonzalez-Peña, C., Uribe, M., & Chávez-Tapia, N. C. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.102158 · Cited by 4
Preliminary insights into gut microbiome shifts as screening proxy for MASLD disease progression
Llirós, M., Buxó, M., Virolés, S., Pujolassos, M., Serra, I., Martínez, J. C., Lluansí, A., Bahí, A., Calle, M. L., & Aldeguer, X. (2026) · Scientific Reports · doi:10.1038/s41598-026-42368-4 · Cited by 3
Gut Microbiota Resilience and Environmental Stressors: A Hidden Key to Lifespan Optimization?
Alum, E. U., Nwachoko, N., Tufail, T., Govindarajan, R. K., Alum, B. N., Nwuruku, O. A., & Aja, P. M. (2026) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-026-10976-1 · Cited by 3
Marwan, A., Elmetwally, O. A., Abass, S. A., Marwan, M. M., El‐Sokkary, M. M. A., & Eissa, L. A. (2026) · Gut Pathogens · doi:10.1186/s13099-026-00826-4 · Cited by 3
Gut microbiota in chronic inflammation: the interplay with lipid mediators
Bao, S., & Yao, C. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2667605 · Cited by 4
Xiang, M., & Hua, Y. (2026) · Frontiers in Oral Health · doi:10.3389/froh.2026.1706821 · Cited by 3
Gallego‐Durán, R., Albillos, A., Ampuero, J., Arechederra, M., Bañares, R., Blas‐García, A., Berná, G., Caparrós, E., Delgado, T. C., Falcón‐Pérez, J. M., et al. (2022) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2022.02.004 · Cited by 3
The role of the intestinal microbiome in inflammation and cancer
Zeißig, S., Frost, F., Haller, D., Stallmach, A., Vehreschild, M. J. G. T., & Schneider, K. M. (2025) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2025.0142 · Cited by 3
Role of bile acids in the prediction of hepatocellular carcinoma in HCV-induced liver cirrhosis
Khalil, A. A., Elsheashaey, A., Abdelsameea, E., Obada, M., Bayomy, F. F. M., & El‐Said, H. (2021) · Egyptian Liver Journal · doi:10.1186/s43066-021-00142-3 · Cited by 3
Gut microbiota changes in nonalcoholic fatty liver disease and concomitant coronary artery disease
Fadieienko, G. D., Gridnyev, O., Kurinna, O. G., & Черелюк, Н. І. (2023) · Cor et Vasa · doi:10.33678/cor.2022.126 · Cited by 3
Nicastro, E., & D’Antiga, L. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-58572-2_7 · Cited by 4
Gut-related molecules as potential biomarkers in patients with decompensated cirrhosis
Barreto, C. M. D. A., do Valle, E. A., Moreira, J. P. D. L., Silva, K. F. E., Rosas, S. L. B., Santana, P. T., Pittella, A. M., Pereira, G., Fernandes, F. F., Perez, R. D. M., et al. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2024.101567 · Cited by 3
Wang, Y., Chen, S., Ye, B., Yang, Z., Liu, Y., Lou, G., Zhou, C., & Zheng, M. (2025) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2025.106786 · Cited by 3
Acharya, C., & Bajaj, J. S. (2020) · Hepatology Communications · doi:10.1002/hep4.1596 · Cited by 3
Divya, K. P., Hari, P., Kanwar, N., Aggarwal, N., Dhoat, P. S., Liu, L., Kanwal, A., & Singh, S. P. (2023) · Advanced Gut & Microbiome Research · doi:10.1155/2023/5431615 · Cited by 2
Non-alcohlic Fatty Liver Disease (NAFLD): Is it a Dormant Volcano or Tip of an Iceberg?
Gupta, P. (2024) · Indian Journal of Community Medicine · doi:10.4103/ijcm.ijcm_174_24 · Cited by 2
Huang, C., Luo, Z.-Z., Huang, W., Lin, L.-P., Yao, Y.-T., Zhuang, H.-X., Xu, Q., & Lai, Y. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i1.102034 · Cited by 2
Common pathogenetic mechanisms of non-alcoholic fatty liver disease and polycystic ovary syndrome
Ilovayskaya, I. (2024) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-230-10-90-97 · Cited by 2
Wang, Y., Lang, R., Li, L., Wen, Y., Gao, M., Zhang, J., Yang, J., Li, Q., Wang, L., Yang, X., et al. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1617931 · Cited by 2
Parida, D., Mishra, S., Mohapatra, A. P., Sethi, M., Das, K. R., Kar, S., Suresh, V., Bhagat, S. J., Mohapatra, A., Halder, S., et al. (2025) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2025.101644 · Cited by 3
Yang, Q., Cai, X., Li, S., & Xiao, Z. (2026) · Food Science & Nutrition · doi:10.1002/fsn3.71451 · Cited by 2
陶雪辉, Liu, J., Li, F., Gao, W., Luo, H., & Wang, K. (2026) · Phytotherapy Research · doi:10.1002/ptr.70298 · Cited by 2
Intestinal neutral ceramidase exacerbates MASH pathogenesis
Wang, T., Chen, L., Lei, C., Song, X., Tuohongerbieke, A., Feng, J., Gasparetto, R. L., Zhang, X., McClain, C. J., Tan, Y., et al. (2026) · eGastroenterology · doi:10.1136/egastro-2026-100417 · Cited by 2
Leke, R., Tan, J. Y., Ling, S., Siddiqui, M., Kakol‐Palm, D., Lindblom, A., Andréasson, A., Pellegrini, G., Söderberg, M. P., Zuydam, N. V., et al. (2026) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2026.101866 · Cited by 2
Schneider, K. M., & Trautwein, C. (2020) · Wiener klinisches Magazin · doi:10.1007/s00740-020-00353-1 · Cited by 3
D’Souza, S. M., Yoo Byung, S., Houston, K. V., Patel, A., Parekh, P. J., & Johnson, D. A. (2021) · Annals of Clinical Gastroenterology and Hepatology · doi:10.29328/journal.acgh.1001030 · Cited by 2
Demidova, T. Y., Скуридина, Д. В., & Pervushina, E. S. (2023) · FOCUS Endocrinology · doi:10.15829/2713-0177-2023-17 · Cited by 2
Sun, Y., & Nie, Q. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21630-5.00013-7 · Cited by 2
Li, K., Wang, J., Dang, M., Ren, R., Fu, M., Wang, J., Zhang, Q., & Zhao, C. (2025) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2025.100585 · Cited by 2
Johira, Y., Nakahara, T., Kinami, T., Yamasaki, S., Kosaka, M., Shirane, Y., Miura, R., Murakami, S., Yano, S., Amioka, K., et al. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02851-y · Cited by 2
Yu, J. H. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0048 · Cited by 2
Bioelectronic Devices for Targeted Drug Delivery and Monitoring of Microbial Electrogenesis
Roy, A. (2023) · Linköping studies in science and technology. Dissertations · doi:10.3384/9789180751551 · Cited by 1
Zvyagintseva, T. D., & Chernobay, A. І. (2023) · Shidnoevropejskij zurnal vnutrisnoi ta simejnoi medicini · doi:10.15407/internalmed2023.02.004 · Cited by 1
Daidouji, Y., Suzuki, S., Wang, X., Fahreza, R. R., Nemoto, E., & Yamada, S. (2024) · Journal of Dental Sciences · doi:10.1016/j.jds.2024.05.028 · Cited by 1
Xie, C., Liu, T., Zhong, Y., Li, Z., Xu, J., Zhao, Z., Wang, X., & Gao, P. (2025) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303396313250904204350 · Cited by 1
Research Advances and Therapeutic Potential of Gut Microbiota in Metabolic Diseases
YUAN, S., Han, G., Qiu, H., Zheng, H., FANG, R., XIE, W., YU, W., & PENG, X. (2026) · Biocell · doi:10.32604/biocell.2026.075338 · Cited by 3
Crespo, J., Vélez, P. A., Alonso‐Peña, M., Cayon, L., Jiménez-González, C., & Iruzubieta, P. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15041325 · Cited by 1
Wei, S., Dong, Y., Zhou, H.-Y., Yang, J., Lu, J.-F., Zhao, Y.-L., Zhao, Y., & Lu, J.-F. (2026) · Inflammation · doi:10.1007/s10753-026-02472-z · Cited by 1
Xiang, G. A. O., Dai, S., Li, J., Wang, T., Sun, X., & Li, P. (2026) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-026-01165-3 · Cited by 1
Pam, P., Safari, M., Hojati, A., Zarrin, R., & Faghfouri, A. H. (2026) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.70344 · Cited by 1
Saha, P., Roy, S., More, M., Bose, D., Trivedi, A., Brooks, B. W., Syn, W., Diehl, A. M., & Chatterjee, S. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2652474 · Cited by 1
Zhou, Z., Mao, Y., Li, J., Yang, J., Zhang, Y., Zhao, Y., & Deng, Y. (2026) · Food & Function · doi:10.1039/d6fo00519e · Cited by 1
Sawada, K., Oates, J. R., Kimura, M., Stankiewicz, T. E., Eom, J., Alarcon, P. C., Chung, H., Damen, M. S. M. A., Ulanowicz, C. J., Wayland, J. L., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.08.018 · Cited by 1
Using metabolomics to develop precision medicine strategies to treat nonalcoholic steatohepatitis
Iruarrizaga‐Lejarreta, M., Arretxe, E., & Alonso, C. (2019) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2019.1685379 · Cited by 1
Heshmati, H. M. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.97568 · Cited by 1
Kaput, J., Monteiro, J. P., Morine, M. J., & Kussmann, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00003-4 · Cited by 2
Chereliuk, N. I. (2019) · Modern Gastroenterology · doi:10.30978/mg-2019-5-26 · Cited by 1
Baradeiya, A. M., Taghlabi, K. M., Saleh, A. N., Manikonda, S., & Salim, S. S. (2023) · Cureus · doi:10.7759/cureus.40849 · Cited by 1
Chronic Liver Disease and Promising Therapeutic Strategy: A Concise Review
Yu, H., Wang, Z., & Zhao, G. (2024) · Pharmacognosy Magazine · doi:10.1177/09731296241228361 · Cited by 1
Liu, W., Cheng, Y., Han, X., Xia, J., Wei, Q., Chang, B., & Li, Q. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1607131 · Cited by 1
Editorial: Systems Biology and Bioinformatics in Gastroenterology and Hepatology
Jansen, P. L. M., Breuhahn, K., Teufel, A., & Dooley, S. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01438 · Cited by 1
Gut Microbiota Changes in Nonalcoholic Fatty Liver Disease and Concomitant Cardiovascular DiseasesPreprint
Kurinna, O. G. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.27.224329 · Cited by 1
De-bugging the system: could antibiotics improve liver transplant outcomes?
Bromberg, J. S., Scalea, J. R., & Mongodin, E. F. (2019) · Journal of Clinical Investigation · doi:10.1172/jci130314
Schneider, K. M., & Trautwein, C. (2020) · Die Gastroenterologie · doi:10.1007/s11377-019-00402-0 · Cited by 1
State of gut microbiota and dietary preferences in obese adolescents
Parkhomenko, L. V., Strashok, L. A., Khomenko, M. A., & Осолодченко, Т. П. (2020) · Acta Medica Leopoliensia · doi:10.25040/aml2020.01.040
Microbiote intestinal et stéatopathie métabolique
Cassard, A., Houron, C., & Ciocan, D. M. (2020) · Nutrition Clinique et Métabolisme · doi:10.1016/j.nupar.2019.12.002
The Microbiota-Gut-Liver Axis: Implications for the Pathophysiology of Liver Disease
Quigley, E. M. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-51709-0_8 · Cited by 1
Nutritional and Botanical Approaches for Nonalcoholic Fatty Liver Disease
Lucius, K. (2020) · Alternative and Complementary Therapies · doi:10.1089/act.2020.29303.klu
Mikrobiom und metabolische Fettlebererkrankung (MeFLD)
Neuwirth, N., Kochenburger, S., & Sina, C. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00725-z
Applications of Fecal Microbiota Transplantation: Emphasis on Clostridioides difficile Infections
Signorette, J. P., de Oliveira, R. T. D., Montiel, J. M., & Longo, P. L. (2021) · International Journal of Nutrology · doi:10.1055/s-0040-1718996
Phospholipids in non-alcoholic fatty liver disease
Skvortsov, V. V., Lunkov, M. V., Tinaeva, R. S., & Skvortsova, E. M. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-6-92-99
Depression and non-alcoholic fatty liver disease: Association and potential mechanisms
Peng, H.-L., Liu, L., Liu, D., & Tan, Y. (2022) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v30.i7.295
Stepanov, Y. М., Zavhorodnia, N. Y., & Zhyhyr, N. O. (2022) · GASTROENTEROLOGY · doi:10.22141/2308-2097.56.1.2022.483
Obesidad y enfermedad hepática grasa no alcohólica en Pediatría.
Soto, G. F. F., de Fernández, C. A., Valero, N. J., Ortiz, E. V. T., Raza, C., Valencia, P., Martínez, A., & Lopez, J. (2019) · Enfermería Investiga · doi:10.29033/enfi.v4i3.590 · Cited by 1
Kousar, A., Damani, S., Anvekar, P., Rajotia, A., Gopalakrishnan, K., Baraskar, B., Modi, V. K., Aedma, K., Agarwal, J., Voruganti, H. V., et al. (2022) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm55620.2022.9995460
Periodontitis and non-alcoholic fatty liver disease: a Mendelian randomisation analysisPreprint
Yu, F., Wu, D., Han, C., Wang, Q., Yang, Y., Li, Y., Qin, R., Xu, L., Chen, Y., & He, D. (2023) · Research Square · doi:10.21203/rs.3.rs-2556093/v1
Personalisierte Therapie der metabolisch assoziierten Fettlebererkrankung
Clusmann, J., Schneider, K. M., Koop, P., Plauth, M., & Schneider, C. V. (2023) · Die Gastroenterologie · doi:10.1007/s11377-023-00701-7
屈, 飏. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1381788
Uncoupling of fat deposition and inflammation during nonalcoholic fatty liver disease
Li, H., Guo, X., Aquino, E., & Wu, C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95582-9.00012-7
Nonalcoholic Fatty Liver Disease, Procalcitonin, and Gut Microbiota: Players in the Same Team
Georgescu, D., Lascu, A., Ioniță, I., Ancusa, O., Ionita, M., Rosca, C. I., Călămar-Popovici, D., & Lighezan, D. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.110134
冯, 琳. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1441127
Metadata
- Authors
- Kolodziejczyk, A. A., Zheng, D., Shibolet, O., & Elinav, E.
- Affiliations
- Weizmann Institute of Science (IL)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Tel Aviv Sourasky Medical Center (IL)
- Corresponding author
- Elinav, Eran
- Venue
- EMBO Molecular Medicine
- Published
- 2018-12-27
- Volume
- 11
- Issue
- 2
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC6365925
- OpenAlex
- W2907493655
- Cited by
- 523
- References
- 125
- Citations by year
- 2026: 30 · 2025: 63 · 2024: 73 · 2023: 94 · 2022: 91 · 2021: 76 · 2020: 71 · 2019: 25
- FWCI
- 4.22
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- European Union's Horizon 2020 (747114)
- European Crohn's and Colitis Organization (ECCO) Fellowship
- Ke Lin Program of the First Affiliated Hospital of Sun Yat‐sen University
- Alexander Grass foundation
- Y. and R. Ungar
- Gurwin Family Fund for Scientific Research
- Crown Endowment Fund for Immunological Research
- Else Kroener‐Fresenius Foundation
- Benoziyo Endowment Fund for the Advancement of Science
- Adelis Foundation
- French National Center for Scientific Research
- European Research Council
- Marie Curie Integration grant
- Rising Tide Foundation
- Helmholtz Foundation
- Canadian Institute of Advanced Research
- The Bill & Melinda Gates Foundation & Howard Hughes Medical Institute
- Abisch‐Frenkel Foundation for the Promotion of Life Sciences
- Leona M. and Harry B. Helmsley Charitable Trust
- German–Israeli Foundation for Scientific Research and Development
- Israel Science Foundation
- Minerva Foundation
- European Foundation for the Study of Diabetes
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, gut microbiota, microbiome, cardiometabolic syndrome, obesity, diabetes mellitus, dyslipidemia, hepatic lipid metabolism, hepatic carbohydrate metabolism, inflammation, gut microbiota metabolites, liver cirrhosis, hepatocellular carcinoma
- MeSH terms
- Gastrointestinal Microbiome, Bacteria, Carcinoma, Hepatocellular, Humans, Liver Cirrhosis, Disease Progression, Carbohydrate Metabolism, Lipid Metabolism, Microbiota, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.